Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-05-03 |
Swedish Orphan Biovitrum - SOBI (Sweden) |
new office in Athens |
|
establishment of a new subsidiary in the EU |
Rare diseases - Genetic diseases |
Establishment of a new subsidiary in the EU |
2017-05-03 |
CARsgen Therapeutics (China) |
CAR T-cell manufacturing facility in Shanghai |
|
opening of new premises |
Cancer - Oncology - Technology - Services |
Opening of new premises |
2017-05-03 |
Gensight Biologics (France) |
chief medical officer |
|
nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Nomination |
2017-05-03 |
Rigontec (Germany) |
chief medical officer |
|
nomination |
Cancer - Oncology |
Nomination |
2017-05-02 |
Celyad (Belgium) Novartis (Switzerland) |
|
|
licensing |
|
Licensing agreement |
2017-05-02 |
Verastem (US - MA) |
|
|
nomination |
Cancer - Oncology |
Nomination |
2017-05-02 |
Txcell (France) Inserm (France) |
Chimeric Antigen Receptor (CAR) engineered CD8+Treg cells (CAR?Tregs) |
|
R&D - research - licensing |
Autoimmune diseases - Transplantation |
Licensing agreement |
2017-05-02 |
Bluebird bio (USA - MA) GSK (UK) |
lentiviral vector platform |
Wiscott-Aldrich syndrome, metachromatic leukodystrophy |
licensing - commercialisation |
Rare diseases - Genetic diseases |
Licensing agreement |
2017-05-02 |
Bluebird bio (USA - MA) Novartis (Swtizerland) |
lentiviral vector platform |
|
licensing |
Cancer - Oncology |
Licensing agreement |
2017-05-02 |
Curevac (Germany) |
|
|
nomination |
|
Nomination |
2017-05-02 |
Acceleron Pharma (USA - CA) |
corporate advisor |
|
nomination |
Rare diseases - Genetic diseases - Neurological diseases |
Nomination |
2017-05-02 |
Santhera Pharmaceuticals (Switzerland) Pharmathen (Greece) |
Raxone® (idebenone) |
Leber's hereditary optic neuropathy (LHON) |
distribution - supply |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Distribution agreement |
2017-05-02 |
Neurovive Pharmaceutical (Sweden) Yungjin Pharm (South Korea) |
KL1333 |
genetic mitochondrial disorders |
licensing |
Rare diseases - Genetic diseases |
Licensing agreement |
2017-05-01 |
Shire (UK - USA) Parion Sciences (USA - NC) |
P-321 |
dry eye disease |
licensing - development - commercialisation |
Ophtalmological diseases |
Licensing agreement |
2017-04-28 |
Molmed (Italy) Megapharm (Israel) |
Zalmoxis® - cell therapy product TK |
adjunctive treatment in hematopoietic stem cell transplantation (HSCT) for patients affected by high risk leukaemia |
licensing -commercialisation |
Cancer - Oncology - Rare diseases - Transplantation |
Commercialisation agreement |
2017-04-27 |
Shire (UK - USA) |
new office in Dublin |
|
opening of new premises |
Rare diseases - Genetic diseases - Hematological diseases |
Opening of new premises |
2017-04-27 |
Agios Pharmaceuticals (USA -MA) Aurigene (India) |
small molecule inhibitors of an undisclosed cancer metabolism target |
|
licensing - research - development - commercialisation |
Cancer - Oncology |
Licensing agreement |
2017-04-27 |
Takeda Pharmaceutical (Japan) Harrington Discovery Institute (USA - OH) |
|
|
research - R&D |
Rare diseases |
Research agreement |
2017-04-27 |
Clovis Oncology (USA - CO) Myriad Genetics (USA - UT) |
BRACAnalysis CDx for use with Rubraca® (rucaparib) |
ovarian cancer |
collaboration |
Cancer - Oncology - Diagnostic |
Collaboration agreement |
2017-04-26 |
Lion Biotechnologies (USA - CA) Pharmacell (The Netherlands) |
TIL (tumor infiltrating lymphocyte) products |
|
manufacturing - production |
Cancer - Oncology |
Production agreement |